In particular, in the lung cancer patient the cfDNA analysis showed the appearance of the T790M-EGFR mutation following gefitinib treatment, thus supporting the hypothesis of a selective pressure linked to the treatment. The gene discussed is EGFR; the disease is lung carcinoma.